Genmab (Otc) (GMAB) has released an update.
Genmab A/S, a prominent biotech firm, has been actively executing its share buy-back program, purchasing shares with the aim to complete the program by December 16, 2024. The company has recently made a series of transactions, acquiring a total of 408,701 shares for a sum of DKK 836 million. This strategic move demonstrates Genmab’s commitment to increasing shareholder value as part of its comprehensive financial strategy.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
